Send us Feedback

Vanda Pharmaceuticals (VNDA)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

VNDA » Topics » Item 8.01. Other Events.

This excerpt taken from the VNDA 8-K filed Jan 22, 2007.

Item 8.01.          Other Events.

          On January 22, 2007, Vanda Pharmaceuticals Inc. issued a press release announcing the exercise by the underwriters of an over-allotment option to purchase an additional 570,000 shares of its common stock, in connection with its public offering that priced on January 19, 2007.  The full text of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

This excerpt taken from the VNDA 8-K filed Dec 7, 2006.

Item 8.01.          Other Events.

          On December 7, 2006, Vanda Pharmaceuticals Inc. issued a press release announcing the top-line results from its Phase III clinical trial of its product candidate iloperidone in schizophrenia.  The full text of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

This excerpt taken from the VNDA 8-K filed Nov 15, 2006.

Item 8.01.     Other Events.

On November 15, 2006, Vanda Pharmaceuticals Inc. issued a press release announcing the top-line results for its Phase III clinical trial of VEC-162 for transient insomnia.  The full text of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

This excerpt taken from the VNDA 8-K filed Aug 30, 2006.

Item 8.01.          Other Events.

          On August 30, 2006, Vanda Pharmaceuticals Inc. issued a press release announcing that the Company has completed enrollment for the Phase III trial of its product candidate iloperidone and also for the Phase III trial of its product candidate VEC-162.  The full text of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

EXCERPTS ON THIS PAGE:

8-K
Jan 22, 2007
8-K
Dec 7, 2006
8-K
Nov 15, 2006
8-K
Aug 30, 2006

RELATED TOPICS for VNDA:

"Item 8.01. Other Events." elsewhere:

Affymax (AFFY)
Anika Therapeutics (ANIK)
BioCryst Pharmaceuticals (BCRX)
Cerus (CERS)
Dyax (DYAX)
Enzon Pharmaceuticals (ENZN)
EPIX Pharmaceuticals (EPIX)
Exelixis (EXEL)
GTC Biotherapeutics (GTCB)
Heska (HSKA)
Endo Pharmaceuticals Solutions Inc. (IDEV)
ImmunoGen (IMGN)
Iomai (IOMI)
Metabasis Therapeutics (MBRX)
Medarex (MEDX)
Micromet (MITI)
Matritech (MZT)
Biota Pharmaceuticals, Inc. (NABI)
NGEN, INC. (NGEN)
ARCA biopharma, Inc. (NUVO)
Omrix Biopharmaceuticals (OMRI)
Pharmacopeia Drug Discovery (PCOP)
Progenics Pharmaceuticals (PGNX)
Protalix BioTherapeutics (PLX)
Savient Pharmaceuticals (SVNT)
Trubion Pharmaceuticals (TRBN)
Tercica (TRCA)
Targacept (TRGT)
SYNAGEVA BIOPHARMA CORP (TRMS)
XenoPort (XNPT)
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki